- uplisting wasn't mentioned as a near-term milestone and mentioned only briefly - we're"preparing to uplist". Possibly because this was a short presentation and the emphasis was intended to be on the pipeline and science. Or maybe seeming eager to get off the OTC doesn't help their lympro negotations?

- in "several discussions" re: lympro monetization.